



## CHF Solutions Submits Patent Application to Improve Venous Blood Flow and Ultrafiltration Efficiency

October 23, 2020

EDEN PRAIRIE, Minn., Oct. 23, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced the submission of a patent application for a new technological advance to the Aquadex SmartFlow™ system to promote venous blood flow in the arm of a patient.

A key advantage of Aquadex™ therapy is its ability to work in a safe and comfortable manner through peripheral venous access in the patient's arm rather than a central vein, a common access point with other systems. The new innovation covered by this patent application encourages blood flow in the veins of the patient's arm and is designed to improve the efficiency of ultrafiltration, leading to a shorter therapy time for the patient and fewer interventions for healthcare providers.

"At CHF Solutions, we are committed to developing innovative solutions that support medical professionals and their patients, and we invest in the protection of these innovations," said John Erb, CEO of CHF Solutions. "Our mission is to change the lives of patients suffering from fluid overload through science, collaboration, and innovation, and we continuously make moves to ensure we never lose sight of that goal."

### About CHF Solutions

CHF Solutions, Inc. (Nasdaq: CHFS) is a medical device company dedicated to improving the lives of patients suffering from fluid overload with its novel ultrafiltration therapy system. The company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow system for ultrafiltration therapy. CHF Solutions is headquartered in Minneapolis, Minn., with wholly-owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.

### About the Aquadex SmartFlow System

The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

### Forward-Looking Statements

Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, that this patent will provide sufficient intellectual property protection and that the underlying technology will improve performance of the Aquadex system. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

### CONTACTS

#### INVESTORS:

Claudia Napal Drayton  
Chief Financial Officer, CHF Solutions, Inc.  
952-345-4205  
[ir@chf-solutions.com](mailto:ir@chf-solutions.com)

#### MEDIA:

Jessica Stebing  
Health+Commerce  
260-336-6202  
[jstebing@healthandcommerce.com](mailto:jstebing@healthandcommerce.com)



Source: CHF Solutions, Inc.